Neogen (FRA:NG2) Beneish M-Score: -4.33 (As of Jun. 24, 2026)


FRA:NG2 Neogen Corp FRA:NG2
68 GF Score
Price €7.65
GF Value €10.66
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Neogen Beneish M-Score?

Neogen FRA:NG2 -4.30% 68 Beneish M-Score is -4.33 as of Jun. 24, 2026. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €10.66 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 765 Medical Devices & Instruments companies, Neogen ranks better than 95.16% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.33 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Neogen's Beneish M-Score or its related term are showing as below:

FRA:NG2' s Beneish M-Score Range Over the Past 10 Years
Min: -4.39   Med: -2.47   Max: -1.9
Current: -4.33

During the past 13 years, the highest Beneish M-Score of Neogen was -1.90. The lowest was -4.39. And the median was -2.47.


Neogen Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Neogen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neogen Beneish M-Score Chart

Neogen Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.42 -2.63 -1.90 -2.42 -4.26

Neogen Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.69 -4.26 -4.39 -4.37 -4.33

FRA:NG2 vs NVCR, ESTA, AXGN: Beneish M-Score Comparison

For the Medical Devices subindustry, Neogen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neogen Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neogen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Neogen's Beneish M-Score falls into.


FRA:NG2
68GF Score
Neogen Corp FRA:NG2
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neogen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Neogen for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8482+0.528 * 1.0804+0.404 * 0.9268+0.892 * 0.8899+0.115 * 0.9632
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0774+4.679 * -0.375698-0.327 * 1.0993
=-4.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb26) TTM:Last Year (Feb25) TTM:
Total Receivables was €116.0 Mil.
Revenue was 178.675 + 194.358 + 179.693 + 199.984 = €752.7 Mil.
Gross Profit was 83.754 + 92.282 + 81.579 + 82.381 = €340.0 Mil.
Total Current Assets was €499.1 Mil.
Total Assets was €2,841.7 Mil.
Property, Plant and Equipment(Net PPE) was €294.1 Mil.
Depreciation, Depletion and Amortization(DDA) was €106.8 Mil.
Selling, General, & Admin. Expense(SGA) was €355.9 Mil.
Total Current Liabilities was €127.4 Mil.
Long-Term Debt & Capital Lease Obligation was €671.1 Mil.
Net Income was -14.382 + -13.774 + 31.214 + -543.06 = €-540.0 Mil.
Non Operating Income was -2.623 + -0.632 + 64.788 + 406.156 = €467.7 Mil.
Cash Flow from Operations was 19.207 + 16.819 + 9.323 + 14.586 = €59.9 Mil.
Total Receivables was €153.7 Mil.
Revenue was 212.16 + 217.845 + 196.786 + 219.034 = €845.8 Mil.
Gross Profit was 105.888 + 106.757 + 95.168 + 104.971 = €412.8 Mil.
Total Current Assets was €529.6 Mil.
Total Assets was €3,874.9 Mil.
Property, Plant and Equipment(Net PPE) was €331.3 Mil.
Depreciation, Depletion and Amortization(DDA) was €114.4 Mil.
Selling, General, & Admin. Expense(SGA) was €371.2 Mil.
Total Current Liabilities was €135.6 Mil.
Long-Term Debt & Capital Lease Obligation was €855.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(115.987 / 752.71) / (153.665 / 845.825)
=0.154093 / 0.181675
=0.8482

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(412.784 / 845.825) / (339.996 / 752.71)
=0.488025 / 0.451696
=1.0804

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (499.14 + 294.07) / 2841.714) / (1 - (529.644 + 331.346) / 3874.883)
=0.720869 / 0.777802
=0.9268

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=752.71 / 845.825
=0.8899

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(114.383 / (114.383 + 331.346)) / (106.796 / (106.796 + 294.07))
=0.25662 / 0.266413
=0.9632

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(355.896 / 752.71) / (371.205 / 845.825)
=0.47282 / 0.438867
=1.0774

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((671.132 + 127.408) / 2841.714) / ((854.981 + 135.552) / 3874.883)
=0.281006 / 0.255629
=1.0993

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-540.002 - 467.689 - 59.935) / 2841.714
=-0.375698

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Neogen has a M-score of -4.51 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -4.33 mean?
Neogen (FRA:NG2) has a Beneish M-Score of -4.33 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Neogen and its competitors. According to the industry distribution chart, Neogen ranks #37 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 4.8%.
Is Neogen's Beneish M-Score too high?
Neogen's current Beneish M-Score is -4.33. Based on the distribution chart, Neogen ranks #37 out of 765 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Beneish M-Score compare to NVCR and ESTA?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #37 out of 765 companies for Beneish M-Score. This places Neogen in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Neogen and its competitors. Neogen's current Beneish M-Score is -4.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.66, compared to a current price of €7.65 — trading 28.2% below its estimated fair value. The current Beneish M-Score is -4.33. Neogen's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Beneish M-Score is -4.33 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neogen (FRA:NG2) Overvalued in 2026?

Based on GuruFocus' analysis, Neogen stock appears to be undervalued. The current stock price of €7.65 is trading 28.2% below its estimated GF Value™ of €10.66. GuruFocus considers Neogen to be Modestly Undervalued.

Key valuation signals for FRA:NG2:

  • Beneish M-Score: -4.33
  • GF Value™: €10.66 vs. price of €7.65 (28.2% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neogen Business Description

Other Exchanges NEOG:USANG2:Germany
Address 620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score

Get the complete analysis for FRA:NG2

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.65
Price
€10.66
GF Value